LifeSci Capital Downgrades Centessa to Market Perform After Eli Lilly Acquisition
LifeSci Capital downgraded Centessa (CNTA) to Market Perform from Outperform after Eli Lilly (LLY) announced an agreement to acquire the company for $38 per share in cash plus a non-transferable contingent value right worth up to $9 per share.
